Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716228 | 1.00 | LMNA (0.40) | LMNAHSD17B10TSHRCYP1A2AKR1C3 | |
| SCHEMBL8419892 | 0.86 | PPARG (0.42) | HSD17B10TSHRCYP1A2POLBALDH1A1 | |
| SCHEMBL15502391 | 0.84 | EPHX1 (0.40) | LMNAHSD17B10TSHRPOLBALDH1A1 | |
| SCHEMBL5046409 | 0.80 | CYSLTR2 (0.44) | ALDH1A1 | |
| SCHEMBL10385792 | 0.80 | CYSLTR2 (0.44) | ALDH1A1 | |
| SCHEMBL28454212 | 0.80 | CYSLTR2 (0.44) | ALDH1A1 | |
| SCHEMBL19946640 | 0.79 | CRHBP (0.44) | LMNAHSD17B10TSHRCYP1A2AKR1C3 | |
| SCHEMBL4071095 | 0.79 | TSHR (0.57) | LMNAHSD17B10TSHRCYP1A2AKR1C3 | |
| SCHEMBL4062734 | 0.79 | LMNA (0.41) | LMNAHSD17B10TSHRCYP1A2AKR1C3 | |
| SCHEMBL1928791 | 0.79 | ACP3 (0.43) | LMNAHSD17B10TSHRCYP1A2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117264101-A | Continuous preparation method of fluorine-containing polymer catalyzed by non-sensitizer | 安徽科芯微流化工科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | claimed |
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4520745-A2 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | Cornell University (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2025035608-A1 | GLUTAMIC ACID UREA COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, NUCLIDE TARGETING PROBE AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION | 厦门大学 | 2025-02-20 | — | — | WO | disclosed |
| EP-3474903-B1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | UNIV CORNELL (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | Clarity Pharmaceuticals Ltd (AU) | 2024-02-15 | — | — | US | disclosed |
| CN-117264101-A | Continuous preparation method of fluorine-containing polymer catalyzed by non-sensitizer | 安徽科芯微流化工科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4196175-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-06-21 | — | — | EP | disclosed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| EP-0725635-A1 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995010271-A2 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | GRPR, OGFR, GHRHR | LMNA 3208/4885HSD17B10 2644/4885TSHR 147/4885 |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | LMNA 2141/4885HSD17B10 2611/4885TSHR 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.